Isofol initiates preclinical evaluation of arfolitixorin with Oncosyne AS
Gothenburg, Sweden, April 28, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has initiated […]
Corporate Information
Invitation to presentation of Isofol´s report for the first quarter of 2023
GOTHENBURG, Sweden, April 25, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for
Isofols appoints Roy Jonebrant as new acting Chief Financial Officer
Gothenburg, Sweden, March 17, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that Roy Jonebrant has been
Isofol initiates a stepwise process for the continued development of its drug candidate arfolitixorin
Gothenburg, Sweden, March 6, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has decided
Isofol’s board appoints Thomas Andersson as new CEO of the company
Gothenburg, Sweden, February 28, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the board of Isofol
Bulletin from Extraordinary General Meeting in Isofol Medical AB (publ) held on February 28, 2023
Today on February 28, 2023 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its Extraordinary General Meeting
Bulletin from Extraordinary General Meeting in Isofol Medical AB (publ) held on February 13, 2023
Today on February 13, 2023 in Gothenburg – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), held its Extraordinary General Meeting
Invitation to presentation of Isofol´s report for the fourth quarter of 2022
GOTHENBURG, Sweden, February 9, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for
Isofol has obtained a request to call for an extraordinary general meeting
GOTHENBURG, Sweden, January 30, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), has obtained a request to call an
Isofol invites to an informational meeting on January 30 prior to extraordinary general meeting
GOTHENBURG, Sweden, January 20, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), yesterday called shareholders to an extraordinary